- Home
- THCH vs INAB Comparison
THCH vs INAB Comparison
Compare THCH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THCH | INAB |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.5M | 10.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | THCH | INAB |
|---|---|---|
| Price | $2.39 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $108.00 |
| AVG Volume (30 Days) | 7.7K | ★ 52.2K |
| Earning Date | 12-09-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $188,274,078.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.95 | $1.53 |
| 52 Week High | $3.82 | $12.53 |
Technical Indicators
Market Signals| Indicator | THCH | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 36.37 |
| Support Level | $2.25 | $1.73 |
| Resistance Level | $2.70 | $1.87 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 31.11 | 3.46 |
Price Performance
Historical ComparisonAbout THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.